Differential gene expression during apoptosis induced by a serum factor: role of mitochondrial F0-F1 ATP synthase complex.
The number of genes that are up regulated or down regulated during apoptosis is large and still increasing. In an attempt to characterize differential gene expression during serum factor induced apoptosis in AK-5 cells (a rat histiocytoma), we found subunit 6 and subunit 8 of the transmembrane proton channel and subunit alpha of the catalytic core of the mitochondrial F(0)-F(1) ATP synthase complex to be up regulated during apoptosis. The increase in the expression levels of these subunits was concomitant with a transient increase in the intracellular ATP levels, suggesting that the increase in cellular ATP content is a result of the increase in the expression of ATP synthase subunits' gene and de novo protein synthesis. Depleting the cellular ATP levels with oligomycin inhibited apoptosis significantly, pointing to the requirement of ATP during apoptosis. Caspase 1 and caspase 3 activity and the loss of mitochondrial membrane potential were also inhibited by oligomycin during apoptosis in these cells, suggesting that the oligomycin induced inhibition of apoptosis could be due to inhibition of caspase activity and inhibition of mitochondrial depolarization. However, cytochrome C release during apoptosis was found to be completely independent of intracellular ATP content. Besides the ATP synthase complex genes, other mitochondrial genes like cytochrome C oxidase subunit II and III also showed elevated levels of expression during apoptosis. This kind of a mitochondrial gene expression profile suggests that in AK-5 cells, these genes are upregulated in a time-linked manner to ensure sufficient intracellular ATP levels and an efficient functioning of the mitochondrial respiratory chain for successful completion of the apoptotic pathway.
Singh
S
S
Centre for Cellular & Molecular Biology, Uppal Road, Hyderabad, 500 007, India.
Khar
A
A
D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics*; D001685:Biological Factors / Q000494:pharmacology*; D061945:Caspase Inhibitors; D045744:Cell Line, Tumor; D003513:Cycloheximide / Q000494:pharmacology; D045304:Cytochromes c / Q000378:metabolism; D003609:Dactinomycin / Q000494:pharmacology; D004790:Enzyme Induction / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation / Q000187:drug effects*; D042541:Intracellular Space / Q000187:drug effects / Q000201:enzymology; D053078:Membrane Potential, Mitochondrial / Q000187:drug effects; D008928:Mitochondria / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D025261:Mitochondrial Proton-Translocating ATPases / Q000096:biosynthesis / Q000235:genetics*; D009840:Oligomycins / Q000494:pharmacology; D014176:Protein Biosynthesis / Q000187:drug effects; D021122:Protein Subunits / Q000096:biosynthesis / Q000235:genetics; D051381:Rats; D044967:Serum / Q000737:chemistry*; D013997:Time Factors
D001685:Biological Factors; D061945:Caspase Inhibitors; D004791:Enzyme Inhibitors; D009840:Oligomycins; D021122:Protein Subunits; D003609:Dactinomycin; D000255:Adenosine Triphosphate; D045304:Cytochromes c; D003513:Cycloheximide; D025261:Mitochondrial Proton-Translocating ATPases